BioXcel: Data Integrity Concerns Muddy Regulatory Outlook (Rating Downgrade) (NASDAQ:BTAI)

MAYBAYBUTTER

Introduction

BioXcel Therapeutics (NASDAQ:BTAI), a biopharma firm based mostly in Connecticut, leverages AI and machine studying to develop progressive therapies for central nervous system and immuno-oncology issues. Its product lineup contains two fundamental choices: IGALMI, an FDA-approved formulation of dexmedetomidine for treating

Chart
Information by YCharts

Back To Top